For more information call Debra Phelps at 267-987-3638, or visit the product Web site: http://www.maternityalert.com.
FDA approves two drug combos for treating HIV The Food and Drug Administration has okayed two fixed-dose combination treatments for HIV-1: Epzicom (abacavir/lamivudine) and Truvada (tenofovir disoproxil/emtricitabine). Controlling HIV/AIDS usually requires simultaneous use of three or more drugs from different classes. Combination products bring together different AIDS drugs in a single medication or co-package to simplify patients' treatment regimens. The two drugs are indicated in combination with other antiretroviral drug products from different classes such as non-nucleoside reverse transcriptase inhibitors or protease inhibitors for treating adults with HIV-1 infection.
Truvada (made by Gilead Sciences, Inc.) is a fixed-dose combination of tenofovir disoproxil fumarate (300 mg) and emtricitabine (200 mg), previously approved individually under the brand names Viread and Emtriva, respectively. Epzicom's approval is based on data showing therapeutic equivalence between the combination product and the individual products. For more information, visit the following Web sites: http://www.fda.gov , http://www.glaxosmithkline.com , and http://www.gilead.com.
For more information, visit the publisher's Web site at http://www.rodalestore.com, then search for the title or author.
Thinner endometrial thickness linked to higher placenta accreta spectrum risk
November 29th 2024A recent study reveals that reduced endometrial thickness significantly increases the risk of placenta accreta spectrum disorders in women without prior cesarean deliveries using assisted reproductive technology.
Read More
Emerging multiplex UTI testing drives Medicare costs amid increased utilization
November 27th 2024A recent study found a sharp rise in Medicare claims for multiplex urinary tract infection testing from 2016 to 2023, underscoring a significant financial impact and the need for further research into its clinical benefits.
Read More
Reduced cost-effectiveness reported from HPV vaccination in mid-adults
November 27th 2024A recent study highlights the reduced cost-effectiveness of expanding human papillomavirus vaccination to adults aged 27 to 45 years compared to younger groups, though targeted strategies for high-risk subgroups indicate benefits.
Read More